glp-1 agonist. GLP-1R and Diabetes Video: Non-insulin injectable antidiabetic drugs
Description
Insulin resistance in T1D could also be related to the insulin administration route
However, adequate adjustment of insulin doses and close monitoring after GLP-1RA initiation may decrease this risk
Eli Lilly , a competitor in the GLP-1 market, is also aiming to expand the use of its tirzepatide , which was approved for type 2 diabetes in 2021 under the brand name MOUNJARO and for weight loss as ZEPBOUND in late 2023
Its why many people on GLP-1 medications report that meals satisfy them for hours when they used to feel hungry again within an hour or two
